The debt ceiling legislation finalized last month calls for significant reductions in federal spending over the next decade.
WASHINGTON-The debt-ceiling legislation finalized last month calls for significant reductions in federal spending over the next decade. A 12-member Joint Select Committee on Deficit Reduction is charged with identifying $1.5 trillion in spending cuts for the next 10 years by late November.
Tax increases and cuts in Medicare, Social Security and other key federal programs are on the table.
If this "super" committee cannot agree on a savings plan, the debt legislation calls for automatic budget cuts to go into effect in 2013, half from defense outlays and half from domestic spending. Medicare would face a 2% across-the-board reduction, which would hit hospitals and doctors as well as Medicare Advantage and prescription drug plans.
Some of the yet-to-be-distributed funds could disappear, including those set aside to start up new, not-for-profit Consumer Operated and Oriented Plans (CO-OPs) to compete in the exchange market. Many believe the CO-OPs will ultimately default on 40% of the government grants and loans.
While Congress was squabbling over the debt ceiling plan, officials in the Department of Health and Human Services (HHS) rolled out new requirements for preventive benefits. The latest list of benefits includes birth control, health screenings and counseling services specific to women. These requirements build on a list of services, such as mammograms, all required under PPACA without any co-pays or deductibles.
Insurers object that offering benefits without cost-sharing will lead to higher healthcare spending and steeper premiums. Critics note that the new mandates won't help women who lack insurance, and don't extend to existing health plans with "grandfathered" status. Catholic church officials and pro-life groups strongly oppose free birth control. And the growing list of benefit mandates raises concerns among plans and payers about the scope of "essential" benefits that HHS is finalizing for all plans sold on state exchanges.
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
Inflation Reduction Act: Reforms to Patient Cost-Sharing
September 18th 2023Lower out-of-pocket costs for patients might put upward pressure on drug prices, as manufacturers face less price sensitivity, note Matthew Majewski and Rhett Johnson of Charles River Associates. But they also note that upward pressure on price is likely to be limited to the inflation rate as any additional price increase would need to be paid back to CMS in the form of inflation rebates.
Read More
Spending climbed by 2.7% in 2021. In 2020, it soared by 10.3%, fueled by federal government spending in response to the pandemic. The blizzard of calculations of 2021 healthcare spending by CMS’ actuaries also provides further evidence that utilization of healthcare services bounced back in 2021.
Read More
Talking PIE, the Act, Before Thanksgiving
November 23rd 2022AMCP CEO Susan A. Cantrell spoke with Managed Healthcare Executive® about Preapproval Information Exchange (PIE) Act of 2022, which would allow drug manufacturers to share information about a drug with payers before the drug is approved. Cantrell says passage of the PIE Act would speed up patient access to new medications.
Read More
Inflation Reduction Act and the Impact on Pharmaceutical Pricing and Investment Decisions
November 21st 2022The reference to “maximum fair price” in the act bodes poorly for manufacturers and suggests more of a take-it-or-leave-it situation rather than a negotiation where clinical evidence would be the prevailing factor in determining price.
Read More